NeuroSense Therapeutics Ltd. cash flow to debt ratio of -4.51K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NeuroSense Therapeutics Ltd.'s free cash flow has increased -24.26% from $-10.14M last year to $-7.68M, signaling increasing performance

NeuroSense Therapeutics Ltd.'s debt to equity ratio is -0.11, signaling that the company spent its equity and risk bankruptcy.

NeuroSense Therapeutics Ltd.'s debt to equity ratio is -0.11, signaling that the company spent its equity and risk bankruptcy.

NeuroSense Therapeutics Ltd. has negative EBITDA, making leverage ratio unreliable

NeuroSense Therapeutics Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

NeuroSense Therapeutics Ltd. has insufficient data to evaluate this check.

NeuroSense Therapeutics Ltd.'s short-term liabilities of $2.52M exceed its short-term assets of $778.00K, signaling financial risk

NeuroSense Therapeutics Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

NeuroSense Therapeutics Ltd.'s return on equity of 1.07K%, is higher than 15.00%, indicating good performance

NeuroSense Therapeutics Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NeuroSense Therapeutics Ltd. has insufficient public price history to evaluate earnings stability.

NeuroSense Therapeutics Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

NeuroSense Therapeutics Ltd. has negative free cash flow, indicating cash burn

NeuroSense Therapeutics Ltd.'s yearly earnings has decreased 8.96% since last year from $-10.21M to $-11.12M, signaling decreasing performance

NeuroSense Therapeutics Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 797.48% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

NeuroSense Therapeutics Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.

NeuroSense Therapeutics Ltd. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

NeuroSense Therapeutics Ltd. has insufficient public price history to evaluate ROE consistency.

NeuroSense Therapeutics Ltd. has insufficient data to evaluate this check.

NeuroSense Therapeutics Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NeuroSense Therapeutics Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

NeuroSense Therapeutics Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

NeuroSense Therapeutics Ltd. has insufficient data to evaluate this check.

NeuroSense Therapeutics Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NeuroSense Therapeutics Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails

NeuroSense Therapeutics Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue